English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, November 30, 2020
Eisai to Present Latest Data on Perampanel at the 74th American Epilepsy Society Annual Meeting
Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies
Friday, November 27, 2020
AbbVie and Eisai Announce an approval for additional indication of HUMIRA
Thursday, November 26, 2020
エーザイ、パーキンソン病患者様の生活をサポートするスマートフォン・アプリ「PaDiCo」の提供開始
Friday, November 20, 2020
エーザイ、人事異動ならびに組織改編(2020年11月20日付)を発表
Wednesday, November 18, 2020
Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2020 for Seventh Time
Eisai: Jyseleca (Filgotinib) for Rheumatoid Arthritis Launches in Japan
エーザイ、社会的責任投資指数「Dow Jones Sustainability Asia Pacific Index」に7回目の選定
ギリアドとエーザイ、日本で関節リウマチに対するJAK阻害剤「ジセレカ(R)錠」を新発売
Monday, November 16, 2020
Eisai Receives Approval for Indication Expansion of Anti-Epileptic Agent Fycompa for Use in Pediatric Patients

Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575